PPIDT00487
Drug Information
| Name | Talquetamab |
|---|---|
| Sequence | EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTSKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFLLYSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK |
| DrugBank_ID | DB16678 |
| Type | biotech |
| Indication | In the US, talquetamab is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.[L47765] This is an accelerated approval indication. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). In Europe, talquetamab is indicated in patients who received at least three prior therapies and have demonstrated disease progression on the last therapy.[L48817] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Subcutaneous |
3 mg/1.5mL
|
| Injection | Subcutaneous |
40 mg/1mL
|
| Injection, solution | Subcutaneous |
2 mg/ml
|
| Injection, solution | Subcutaneous |
40 mg/ml
|
| Solution | Subcutaneous |
2 mg / mL
|
| Solution | Subcutaneous |
40 mg / mL
|